1. Home
  2. SGLD vs BOLD Comparison

SGLD vs BOLD Comparison

Compare SGLD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scorpio Gold Corporation American Depositary Shares

SGLD

Scorpio Gold Corporation American Depositary Shares

N/A

Current Price

$3.21

Market Cap

62.0M

Sector

N/A

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.51

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SGLD
BOLD
Founded
N/A
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
62.0M
54.5M
IPO Year
2009
2024

Fundamental Metrics

Financial Performance
Metric
SGLD
BOLD
Price
$3.21
$2.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.1K
★ 115.4K
Earning Date
11-12-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.96
52 Week High
$5.45
$3.16

Technical Indicators

Market Signals
Indicator
SGLD
BOLD
Relative Strength Index (RSI) 36.42 53.40
Support Level N/A $2.43
Resistance Level $3.70 $2.65
Average True Range (ATR) 0.20 0.10
MACD 0.01 0.02
Stochastic Oscillator 7.71 56.82

Price Performance

Historical Comparison
SGLD
BOLD

About SGLD Scorpio Gold Corporation American Depositary Shares

Scorpio Gold Corp is a company that is engaged in mineral exploitation, exploration, and development in the United States. It holds an interest in the Mineral Ridge gold project, which is located in the northwest of the town of Silver Peak and west of Tonopah in Esmeralda County, Nevada. Its other project includes the Goldwedge property, which is located north-northeast of the town of Tonopah within the Manhattan Mining District of south-central Nevada.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: